Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit monoclonal antibody anti-Cd109 antigen is suitable for use in Western Blot research applications. |
Clonality: |
Monoclonal |
Clone ID: |
S5222RM |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.05% Proclin300, 0.05% BSA, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:1000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Tissue Specificity | Widely expressed with high level in uterus, aorta, heart, lung, trachea, placenta and in fetal heart, kidney, liver, spleen and lung. Expressed by CD34(+) acute myeloid leukemia cell lines, T-cell lines, activated T-lymphoblasts, endothelial cells and activated platelets. Isoform 4 is expressed in placenta. Isoform 1 is expressed in keratinocytes and placenta. |
Post Translational Modifications | N-glycosylated. 2 forms of 150 (p150) and 120 kDa (p120) exist due to proteolytic degradation from a 180 kDa form. |
Function | Modulates negatively TGFB1 signaling in keratinocytes. |
Protein Name | Cd109 Antigen150 Kda Tgf-Beta-1-Binding ProteinC3 And Pzp-Like Alpha-2-Macroglobulin Domain-Containing Protein 7Platelet-Specific Gov AntigenP180R150Cd Antigen Cd109 |
Database Links | Reactome: R-HSA-114608Reactome: R-HSA-163125 |
Cellular Localisation | Cell MembraneLipid-AnchorGpi-Anchor |
Alternative Antibody Names | Anti-Cd109 Antigen antibodyAnti-150 Kda Tgf-Beta-1-Binding Protein antibodyAnti-C3 And Pzp-Like Alpha-2-Macroglobulin Domain-Containing Protein 7 antibodyAnti-Platelet-Specific Gov Antigen antibodyAnti-P180 antibodyAnti-R150 antibodyAnti-Cd Antigen Cd109 antibodyAnti-CD109 antibodyAnti-CPAMD7 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance